ApprovedFDA approval

Hibsago (bepirovirsen)

GlaxoSmithKline (GSK)

Marketer take

An antisense add-on used with existing antiviral therapy in chronic hepatitis B, a market long limited to oral suppressive drugs, so hepatologist and ID education on which patients qualify will be central.

Sponsor company
GlaxoSmithKline (GSK)
Indication
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
Therapeutic area
Infectious disease
Event
FDA approval
Date
Oct 20, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move